LY4256984 + Placebo
Phase 1Recruiting 0 watching 0 views this week💤 Quiet
33
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
ALS (Amyotrophic Lateral Sclerosis)
Conditions
ALS (Amyotrophic Lateral Sclerosis)
Trial Timeline
Aug 5, 2025 → Sep 1, 2027
NCT ID
NCT07100119About LY4256984 + Placebo
LY4256984 + Placebo is a phase 1 stage product being developed by Eli Lilly for ALS (Amyotrophic Lateral Sclerosis). The current trial status is recruiting. This product is registered under clinical trial identifier NCT07100119. Target conditions include ALS (Amyotrophic Lateral Sclerosis).
Hype Score Breakdown
Clinical
10
Activity
5
Company
10
Novelty
3
Community
2
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT07100119 | Phase 1 | Recruiting |
Competing Products
1 competing product in ALS (Amyotrophic Lateral Sclerosis)
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Tofersen | Biogen | Phase 2 | 49 |